<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01204710</url>
  </required_header>
  <id_info>
    <org_study_id>13938</org_study_id>
    <secondary_id>I5B-IE-JGDD</secondary_id>
    <secondary_id>CP15-0805</secondary_id>
    <secondary_id>2009-018015-11</secondary_id>
    <nct_id>NCT01204710</nct_id>
  </id_info>
  <brief_title>A Study of IMC-3G3 in Prostate Cancer</brief_title>
  <official_title>A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody IMC-3G3 Plus Mitoxantrone Plus Prednisone or Mitoxantrone Plus Prednisone in Metastatic Castration-Refractory Prostate Cancer Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study evaluating the safety and efficacy of the monoclonal antibody IMC-3G3 plus
      mitoxantrone plus prednisone compared to mitoxantrone plus prednisone in metastatic
      castration-refractory prostate cancer following disease progression or intolerance on
      docetaxel-based chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Approximately 21 months</time_frame>
    <description>PFS is measured from randomization to the earliest date of the following events: tumor progression according to RECIST v.1.1, unequivocal evidence of progression by bone scan, clinical progression, or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 21 months</time_frame>
    <description>Overall survival time is measured as randomization to date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 21 months</time_frame>
    <description>Proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR) compared to the total number of participants. Best response is categorized using the Response Evaluation Criteria In Solid Tumors (RECIST) (ver 1.1) guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Androgen (PSA) response rate</measure>
    <time_frame>Approximately 21 months</time_frame>
    <description>Proportion of participants with a decrease in PSA from pretreatment to any time point, requiring confirmation no less than 3 weeks after the initial suggestion of response and occuring prior to documentation of PD. Additionally, a PSA response rate equal to the proportion of participants with a decrease in PSA from pretreatment to week 12 or earlier for those who discontinue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary Listing of Participants Reporting Treatment-Emergent Adverse Events</measure>
    <time_frame>Approximately 21 months</time_frame>
    <description>Summary listing of Participants Reporting Treatment-Emergent Adverse Events that received IMC-3G3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Tumor Cells and PDGFRα expression</measure>
    <time_frame>Approximately 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) cycles 1, 2, 3, and 4</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Anti-IMC-3G3 Antibody Assessment (immunogenicity)</measure>
    <time_frame>Approximately 21 months</time_frame>
    <description>Screen for the development of circulating antibodies against IMC-3G3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>IMC-3G3 + Mitoxantrone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 cycle = 3 weeks (21 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitoxantrone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 cycle = 3 weeks (21 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-3G3</intervention_name>
    <description>15mg/kg I.V. Days 1 and 8</description>
    <arm_group_label>IMC-3G3 + Mitoxantrone</arm_group_label>
    <other_name>Olaratumab</other_name>
    <other_name>LY3012207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>Mitoxantrone 12 mg/m2 I.V. Day 1
Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m2)</description>
    <arm_group_label>IMC-3G3 + Mitoxantrone</arm_group_label>
    <arm_group_label>Mitoxantrone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically-confirmed adenocarcinoma of the prostate

          -  radiographic evidence of metastatic prostate cancer (stage M1 or D2)

          -  has prostate cancer unresponsive or refractory to medical or surgical castration with
             a serum testosterone level of &lt; 50 ng/mL

          -  has had disease progression or intolerance on docetaxel-based therapy

          -  PSA ≥ 10 ng/mL

          -  all clinically significant toxic effects of prior surgery, radiotherapy, chemotherapy
             or hormonal therapy have resolved to ≤ Grade 1, based on National Cancer Institute
             Common Terminology Criteria for Adverse Events (NCI CTCAE) v 4.02

          -  patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

          -  adequate hematologic function

          -  adequate hepatic function

          -  adequate renal function

          -  urinary protein is ≤ 1 on dipstick or routine analysis

          -  life expectancy of more than 3 months

          -  fertile man with partners that are women of childbearing potential must use an
             adequate method of contraception during the study

          -  signed Informed Consent document

        Exclusion Criteria:

          -  concurrent active malignancy other than adequately treated nonmelanomatous skin cancer
             or other noninvasive or in situ neoplasms

          -  The patient has received more than 1 prior cytotoxic chemotherapy regimen for
             metastatic disease

          -  prior therapy with mitoxantrone for advanced prostate cancer

          -  The patient has a history of symptomatic congestive heart failure or has a pre study
             echocardiogram or multigated acquisition scan with left ventricular ejection fraction
             that is ≥ 10% below the lower limit of normal institutional range

          -  history of prior treatment with other agents that directly inhibit PDGF or
             platelet-derived growth factor receptors

          -  known allergy to any of the treatment components: IMC 3G3, mitoxantrone, and/or
             prednisone

          -  radiotherapy within 21 days prior to first dose of IMC-3G3

          -  any investigational therapy within 30 days of randomization

          -  is receiving corticosteroids at a dose &gt; 5 mg prednisone orally (PO) 2 times per day
             (BID) or equivalent

          -  received prior strontium-89, rhenium-186, rhenium-188, or samarium-153 radionucleotide
             therapy and has either ongoing evidence of bone marrow dysfunction or poorly
             controlled bone pain

          -  has any ongoing or active infection, symptomatic congestive heart failure, unstable
             angina pectoris, serious cardiac arrhythmia, psychiatric illness, active bleeding or
             pathological condition that carries a high risk of bleeding, or any other serious
             uncontrolled medical disorders

          -  known or suspected brain or leptomeningeal metastases

          -  known human immunodeficiency virus infection or acquired immunodeficiency
             syndrome-related illness
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Aachen</city>
        <zip>57074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Bonn</city>
        <zip>53177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Trento</city>
        <zip>38100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Poznań</city>
        <zip>61-485</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>7014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Pamplona - Navarra</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Sabadell - Barcelona</city>
        <zip>8208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2010</study_first_submitted>
  <study_first_submitted_qc>September 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2010</study_first_posted>
  <disposition_first_submitted>January 22, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 22, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 17, 2014</disposition_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 18, 2016</submitted>
    <returned>January 13, 2017</returned>
    <submitted>March 3, 2017</submitted>
    <returned>April 14, 2017</returned>
    <submitted>March 2, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

